Monitoring with Hevylite® correlates with clinical outcome in myeloma
Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients
M Michallet et al. Leukemia advance online publication 21 July 2017
The prestigious scientific journal “Leukemia” has published the French Myeloma Group (IFM) data supporting Hevylite for monitoring in multiple myeloma patients. This paper highlights the utility of Hevylite (HLC), both in assessment of response to therapy and also for its use in measuring immune recovery following therapy.
Over 450 multiple myeloma patients had their clinical response at the end of consolidation therapy classified by either Hevylite or standard IMWG criteria (e.g. electrophoresis). Results and progression free survival were compared.
“Our results suggest that standard assessment may underestimate responses in a significant proportion of patients, and that HLC monitoring may be a more suitable tool for identifying patients achieving a ≥ CR [complete response]”
“…HLC results were supported by MRD [minimal residual disease] assessment in bone marrow samples using multiparametric flow cytometry…”
Their own results and other’s position Hevylite measurements as an indicator of both residual tumour cells and normalisation of the immune system.
The paper is available to download here. http://www.nature.com/leu/journal/vaop/naam/abs/leu2017209a.html
Find out more about Hevylite